OTCMKTS:HCYTD H-CYTE (HCYTD) Stock Price, News & Analysis $2.02 -1.98 (-49.50%) As of 07/11/2022 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About H-CYTE Stock (OTCMKTS:HCYTD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get H-CYTE alerts:Sign Up Key Stats Today's Range$2.02▼$2.7750-Day Range$2.02▼$2.0252-Week Range$2.02▼$77.00Volume400 shsAverage Volume103 shsMarket Capitalization$521,160.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewH-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.Read More… Receive HCYTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter. Email Address HCYTD Stock News HeadlinesHere are all of the dragons in 'House of the Dragon' and who they belong toJuly 19, 2024 | businessinsider.comHydro One Limited (H.TO)May 28, 2024 | finance.yahoo.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 14, 2025 | Brownstone Research (Ad)W.H. Hamilton Struck by a Train.May 25, 2024 | nytimes.comThe best H&R Block DIY income tax filing options for last-minute filers in 2024April 12, 2024 | cbsnews.comH&R Block Review 2024: The Best Free Online Tax Filing ExperienceMarch 1, 2024 | cnet.comH&R Block Coupons February 2024February 14, 2024 | forbes.comHyatt Hotels Corp Class A HNovember 2, 2023 | morningstar.comSee More Headlines HCYTD Stock Analysis - Frequently Asked Questions How have HCYTD shares performed this year? H-CYTE's stock was trading at $2.02 at the start of the year. Since then, HCYTD stock has increased by 0.0% and is now trading at $2.02. View the best growth stocks for 2025 here. How do I buy shares of H-CYTE? Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & Medical Instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:HCYTD CIK1591165 Webwww.hcyte.com Phone(844) 633-6839FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,800,000.00 Net Margins-450.40% Pretax Margin-450.40% Return on EquityN/A Return on Assets-777.68% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$1.61 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value($31.45) per share Price / Book-0.06Miscellaneous Outstanding Shares258,000Free Float244,000Market Cap$521,160.00 OptionableNot Optionable Beta1.12 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (OTCMKTS:HCYTD) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s third-term comments grabbed headlines, but the bigger story is what he’s planning next. A new report ...Porter & Company | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredA New Economic Shift – How You Can PrepareWhile everyone's focused on the Fed and interest rates... most investors are missing the real story. There'...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredDrop these 5 stocks now!You think the volatility is over? Think again … Because it’s just getting started. In fact, according...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H-CYTE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share H-CYTE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.